Navigation Links
Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
Date:12/17/2007

owing administration of the standard dose of trastuzumab.

Of 26 patients enrolled in the trial, 20 were evaluable for efficacy (3 patients were not evaluable for efficacy and 3 patients are too early to assess). Of the 26 patients enrolled, 21 were treated with Kosan's prior Cremophor(R)-containing injection formulation of tanespimycin (4 of whom were crossed over to receive the recently introduced Injectable Suspension formulation), and 5 were treated with the Injectable Suspension formulation (3 of whom were recently enrolled and are not yet evaluable). Of the 20 patients evaluable for efficacy, 11 responded, yielding a clinical benefit rate of 55%.

-- 5 patients experienced confirmed partial responses, including,

-- 1 patient with 75% decrease in liver metastases with 42% drop in

CEA; 8 months on study;

-- 1 patient with 45% decrease in a hilar node, continuing on study

after 14 months;

-- 1 patient with 33% decrease in right breast lesions with decreased

tumor markers, continuing on study after 7 months;

-- 1 patient with 57% decrease in lymph nodes, liver and left breast

lesions, continuing on study after 7 months; and

-- 1 patient with 37% decrease in lymph nodes, continuing on study

after 5 months.

-- 2 patients experienced minor responses with decreased tumor markers (on

study for 6 and 5 months).

-- 4 patients had stable disease for 4, 4, 7, and 8 months.

Common toxicities were mainly Grade 1 and 2 and included diarrhea, fatigue, dizziness and headache. Treatment-related Grade 3 toxicities were experienced by 3 patients and included reversible fatigue and headache, increased liver function tests that resolved in 9 days and unsteady gait and euphoric mood that resolved in a single day. Noticeably absent were toxicities associated with conventional chemotherapy, including alopecia, mye
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
2. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
3. 3 strikes, youre out? Refiling of Amendment to Change Constitution to Criminalize Stem Cell Cures Shows Trouble with Anti-Cures Cause
4. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
5. International Survey Shows People Over Forty Ignore Risk of Blindness
6. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
7. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
8. Video shows buckyballs form by shrink wrapping
9. National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 Cynvenio, a ... management through the genomic analysis of tumor cells in ... Finder™, a web-based cancer decision support application powered by ... with Cynvenio’s ClearID™ genomic test, Therapy Finder will provide ...
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... ... Terrosa Technologies, a provider of Cloud and SaaS migration ... wide sales, marketing and distribution responsibilities with Integrated Clinical Solutions ... Clinical Trial Management System (CTMS) tool for the pharmaceutical clinical ...
... , , , ... (OTC Bulletin Board: ADLS) announced that it received a complete ... (FDA) regarding its New Drug Application (NDA) for Restanza(TM) (cethromycin) ... pneumonia (CAP). In its letter, the FDA indicated that ...
... Novavax, Inc. (Nasdaq: NVAX ) today announced that it ... release to be issued after 8:00 a.m. Eastern Time on Friday, ... to discuss its financial results at 10:00 a.m. Eastern Time on ... President and Chief Executive Officer Dr. Rahul Singhvi and other members ...
Cached Biology Technology:Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 2Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 3Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia 2Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia 3Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia 4Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia 5
(Date:7/9/2014)... studies suggest that children delivered by Caesarean section have a ... it is still unknown why this is the case and ... Faculty of Health and Medical Sciences therefore decided to scrutinise ... system in a study of newborn mouse pups. ... section had developed a lower number of cells that strengthen ...
(Date:7/9/2014)... switch out one gene for another in a line ... fiction to reality within this decade. As with any ... of fixing disease-causing genes in humans, for example--as well ... put one of those concerns to rest: using gene-editing ... of mutations in the cells. The new results were ...
(Date:7/9/2014)... in Indiana state parks have helped restore the health ... overabundant populations of white-tailed deer, a Purdue study shows. ... professor of forest ecology, found that a 17-year-long Indiana ... state parks has successfully spurred the regrowth of native ... deer. , Jenkins said that while hunting may ...
Breaking Biology News(10 mins):Mouse study: Natural birth may strengthen the immune system 2No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Hunting gives deer-damaged forests in state parks a shot at recovery 2
... color, their knobby knees or their big feet to their children ... through those same genes. New research from the University of ... herpes virus 6 (HHV-6) to their children because it is integrated ... been shown to become part of the human DNA and then ...
... wolves chasing deer and other hoofed animals, new research ... to hunting. The study, published today in the open ... salmon is available, wolves will reduce deer hunting activity ... the University of Victoria and the Raincoast Conservation Foundation, ...
... permafrost in northern latitudes, which greatly increases microbial decomposition ... of warming in the region and could become a ... thus further warming, according to a new assessment in ... study, by Edward A. G. Schuur of the University ...
Cached Biology News:Virus weaves itself into the DNA transferred from parents to babies 2Wolves would rather eat salmon 2Thawing permafrost likely to boost global warming 2
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
PFM8 Antibody...
Goat anti-PITPN Class: Antibody Product Group: Miscellaneous Antibody...
Biology Products: